A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
Key Details
- 1AI tool SÉMIL uses pathology slide images and written descriptions to stratify relapse risk for stage II bowel cancer patients.
- 2Validated on over 1220 patients across three independent cohorts and multiple Australian institutions.
- 3Greatest predictive accuracy when AI assessments align with pathologist evaluations.
- 4Can be integrated into existing clinical digital pathology workflows, supporting but not replacing human clinicians.
- 5Findings published in Gastroenterology (July 2026) with no conflicts of interest reported.
- 6Research involved collaboration among several top Australian institutions and cancer centers.
Why It Matters
Accurate risk stratification can ensure high-risk stage II bowel cancer patients receive timely, potentially life-saving therapy, while sparing low-risk patients from unnecessary treatment. The study demonstrates how AI can augment pathology workflows for more consistent, data-driven clinical decisions in oncology.
Source
EurekAlert
Related News
•EurekAlert
UVA's $4M NIH Grant Backs AI to Optimize Cardiac MRI Therapies
UVA secures $4 million NIH funding to develop GenStrain, an AI model using MRI data to personalize cardiac pacing therapies.
•EurekAlert
Machine Learning Models Predict Cancer Risk with Routine Health Data
Researchers developed machine learning models using routinely collected health data to predict individual risk for 20 common cancers, outperforming traditional methods for several cancer types.
•EurekAlert
Duke Receives $25M to Lead National Trustworthy AI Hub for Dementia and Aging
Duke University has launched a $25 million national center to make AI for aging and dementia clinically robust and trustworthy.